PD-L1 assessment in urothelial carcinoma: a practical approach

Five programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Due to restrictions by the FDA and EMA first-line treatment with Atezolizumab and Pembro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Transl Med
Egile Nagusiak: Eckstein, Markus, Cimadamore, Alessia, Hartmann, Arndt, Lopez-Beltran, Antonio, Cheng, Liang, Scarpelli, Marina, Montironi, Rodolfo, Gevaert, Thomas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2019
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6944605/
https://ncbi.nlm.nih.gov/pubmed/31930091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.10.24
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak